We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Recommendations on Pre-IND Meetings for Rare Disease Drugs
FDA Issues Recommendations on Pre-IND Meetings for Rare Disease Drugs
The FDA released draft guidance Monday on how sponsors of treatments of rare diseases can get more from their pre-investigational new drug meetings with the agency.